
Browsing restrictions can be lifted for a fee.
-3.52%
Volitionrx limited
0.05%
Avg of Sector
-0.31%
S&P500

Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2026Q1 | ||||
| 2026Q2 | ||||
| 2026Q3 | ||||
| 2026Q4 | ||||
| 2027Q1 |
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2025Q4 | |||||||
| 2025Q3 | |||||||
| 2025Q2 | |||||||
| 2025Q1 |
The most recent financial report for Volitionrx limited (VNRX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating VNRX's short-term business performance and financial health. For the latest updates on VNRX's earnings releases, visit this page regularly.
According to the latest financial report, Volitionrx limited (VNRX) reported an Operating Profit of -5.1M with an Operating Margin of -813.2% this period, representing a growth of 13.08% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, Volitionrx limited (VNRX) announced revenue of 627.28K, with a Year-Over-Year growth rate of 32.19%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
As of the end of the reporting period, Volitionrx limited (VNRX) had total debt of 11.26M, with a debt ratio of 1.75. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
At the end of the period, Volitionrx limited (VNRX) held Total Cash and Cash Equivalents of 199.41K, accounting for 0.03 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, Volitionrx limited (VNRX) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -813.2%%, and net margin of -857.4%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess VNRX's profit trajectory and future growth potential.
According to the past four quarterly reports, Volitionrx limited (VNRX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.05. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
Volitionrx limited (VNRX)'s Free Cash Flow (FCF) for the period is -3.63M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 34.28% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
The latest valuation data shows Volitionrx limited (VNRX) has a Price-To-Earnings (PE) ratio of -1.9 and a Price/Earnings-To-Growth (PEG) ratio of 0.19. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.